Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Propel Bio Partners does not develop drugs directly but invests in and supports life science companies advancing disruptive therapies and technologies to improve human health. Its portfolio includes companies working on microbiome-based medicine and male reproductive health.
Example portfolio highlights:
The firm provides financial support as well as access to an ecosystem of medical experts, operational advisors, and service providers.
Recent investment activity includes leading a $60M PIPE round for Achieve Life Sciences in February 2024.
No direct clinical results or pipeline since it’s an investment firm.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Propel Bio Partners.